<DOC>
	<DOCNO>NCT00482989</DOCNO>
	<brief_summary>To evaluate safety tolerability multiple IV dose MEDIMUNNE antibody adult patient SLE .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Multiple Intravenous Doses MEDI 545 Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability multiple IV dose MEDI-545 adult patient SLE .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female adult ≥ 18 year age time first dose study drug ; Written inform consent obtain patient ; patient 's legal representative ; Meet least 4 11 revise ACR classification criterion SLE ( see Appendix A ) ( ACR,1999 ) ; Have positive ANA test ≥ 1:80 serum dilution past screening ; Have least one system score A two system score B BILAG index screening , SELENASLEDAI score ≥ 6 ; Sexually active woman , unless surgically sterile ( include tubal ligation ) least 2 year postmenopausal , must use effective method avoid pregnancy ( include oral , injectable , transdermal , implanted contraceptive , intrauterine device , diaphragm spermicide , cervical cap , abstinence , sterile sexual partner ) addition use condom ( male female condom spermicide ) screen end study . Cessation birth control point discuss responsible physician . Sexually active men , unless surgically sterile , must likewise practice two effective method birth control ( condom spermicide abstinence ) must use precaution Study Day 0 end study . Ability complete study period , include followup period Study Day 350 ; Willing forego form experimental treatment study . Have receive MEDI545 within 120 day prior screen either detectable level MEDI545 antiMEDI545 antibody ( positive &gt; 1:10 serum dilution ) serum screen ; History allergy reaction component study drug formulation ; Have receive prednisone &gt; 20 mg/day ( equivalent dose another oral corticosteroid ) within 14 day randomization/entry ; Have receive follow dosage medication within 28 day randomization/entry : hydroxychloroquine &gt; 600 mg/day , mycophenolate mofetil &gt; 3 g/day , methotrexate &gt; 25 mg/week , azathioprine &gt; 3 mg/kg/day , dose cyclophosphamide , cyclosporine , thalidomide ; Have receive leflunomide &gt; 20 mg/day 6 month prior Study Day 0 ; Have receive fluctuating dos antimalarial , mycophenolate mofetil , methotrexate , leflunomide , azathioprine within 28 day randomization/entry fluctuate dos NSAIDs oral corticosteroid within 14 day randomization/entry ; Treatment investigational drug therapy within 28 day randomization/entry study , B celldepleting therapy within 12 month randomization/entry , biologic therapy within 30 day 5 halflives biologic agent , whichever longer , randomization/entry study ; In investigator 's opinion , evidence clinically significant active infection , include ongoing , chronic infection , within 28 day randomization/entry ; A history severe viral infection judge investigator , include severe infection either cytomegalovirus herpes family disseminate herpes , herpes encephalitis , ophthalmic herpes ; Herpes zoster infection within 3 month randomization/entry ; Evidence infection hepatitis B C virus , HIV1 HIV2 , active infection hepatitis A , determined result test screening ; Vaccination live attenuate virus within 28 day randomization/entry ; Pregnancy ( woman , unless surgically sterile least 2 year postmenopausal , must negative serum pregnancy test within 28 day receive study drug negative urine pregnancy test Study Day 0 receive study drug ) ; Breastfeeding lactate woman ; History primary immunodeficiency ; History alcohol drug abuse &lt; 1 year prior randomization/entry ; History cancer ( except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy &gt; 1 year prior randomization/entry ) ; History active TB infection ; History latent TB infection newly positive TB skin test ( reaction define ≥ 10 mm diameter systemic immunosuppressive medication ≥ 5 mm systemic immunosuppressive medication ) without completion appropriate course treatment ongoing prophylactic therapy ; Elective surgery plan time screen Study Day 196 ; At screen blood test ( within 28 day randomization/entry ) , follow : AST &gt; 2 × upper limit normal range ( ULN ) , unless cause SLE , determine investigator , ALT &gt; 2 × ULN , unless cause SLE , determine investigator , Creatinine &gt; 4.0 mg/dL , Neutrophils `` 1,500/ μL ( &lt; 1.5 × 109/L ) '' Platelet count `` Platelet count &lt; 50,000/ μL ( &lt; 50 × 109/L ) '' History disease , evidence current disease ( SLE ) , find upon physical examination , laboratory abnormality , opinion investigator medical monitor , may compromise safety patient study confound analysis study ; Any employee research site involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>